|
1
|
Kuhlmann JD, Rasch J, Wimberger P and
Kasimir-Bauer S: microRNA and the pathogenesis of ovarian cancer -
a new horizon for molecular diagnostics and treatment? Clin Chem
Lab Med. 50:601–615. 2012.PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yakirevich E, Sabo E, Naroditsky I, Sova
Y, Lavie O and Resnick MB: Multidrug resistance-related phenotype
and apoptosis-related protein expression in ovarian serous
carcinomas. Gynecol Oncol. 100:152–159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wenham RM, Lapolla J, Lin HY, Apte SM,
Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A,
Havrilesky LJ and Secord AA: A phase II trial of docetaxel and
bevacizumab in recurrent ovarian cancer within 12 months of prior
platinum-based chemotherapy. Gynecol Oncol. 130:19–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morin PJ: Drug resistance and the
microenvironment: Nature and nurture. Drug Resist Updat. 6:169–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brabec V and Kasparkova J: Molecular
aspects of resistance to antitumor platinum drugs. Drug Resist
Updat. 5:147–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong L, Yang Z, Ma J and Fan D: Function
of miRNA in controlling drug resistance of human cancers. Curr Drug
Targets. 14:1118–1127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barbarotto E, Schmittgen TD and Calin GA:
MicroRNAs and cancer: Profile, profile, profile. Int J Cancer.
122:969–977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagaraja AK, Creighton CJ, Yu Z, Zhu H,
Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM,
et al: A link between mir-100 and FRAP1/mTOR in clear cell ovarian
cancer. Mol Endocrinol. 24:447–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng B, Wang R and Chen L-B: MiR-100
resensitizes docetaxel-resistant human lung adenocarcinoma cells
(SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 317:184–191.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang W, Lee DY and Ben-David Y: The roles
of microRNAs in tumorigenesis and angiogenesis. Int J Physiol
Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI
|
|
16
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan JK, Blansit K, Kiet T, Sherman A,
Wong G, Earle C and Bourguignon LY: The inhibition of miR-21
promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol
Oncol. 132:739–744. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang YQ, Guo RD, Guo RM, Sheng W and Yin
LR: MicroRNA-182 promotes cell growth, invasion, and
chemoresistance by targeting programmed cell death 4 (PDCD4) in
human ovarian carcinomas. J Cell Biochem. 114:1464–1473. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Huang L, Zhao Y and Tan W:
Downregulation of miR-130a contributes to cisplatin resistance in
ovarian cancer cells by targeting X-linked inhibitor of apoptosis
(XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 45:995–1001.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cochrane DR, Howe EN, Spoelstra NS and
Richer JK: Loss of miR-200c: A marker of aggressiveness and
chemoresistance in female reproductive cancers. J Oncol.
2010.8217172010.doi: 10.1155/2010/821717. PubMed/NCBI
|
|
21
|
Shi W, Alajez NM, Bastianutto C, Hui AB,
Mocanu JD, Ito E, Busson P, Lo KW, Ng R, Waldron J, et al:
Significance of Plk1 regulation by miR-100 in human nasopharyngeal
cancer. Int J Cancer. 126:2036–2048. 2010.PubMed/NCBI
|
|
22
|
Liu J, Lu KH, Liu ZL, Sun M, De W and Wang
ZX: MicroRNA-100 is a potential molecular marker of non-small cell
lung cancer and functions as a tumor suppressor by targeting
polo-like kinase 1. BMC Cancer. 12:5192012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang
X, Zhou W, Wu W and Li Q: Reduced expression of microRNA-100
confers unfavorable prognosis in patients with bladder cancer.
Diagn Pathol. 7:1592012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen P, Zhao X and Ma L: Downregulation of
microRNA-100 correlates with tumor progression and poor prognosis
in hepatocellular carcinoma. Mol Cell Biochem. 383:49–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang H, Kong W, He L, Zhao JJ, ODonnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wyman SK, Parkin RK, Mitchell PS, Fritz
BR, OBriant K, Godwin AK, Urban N, Drescher CW, Knudsen BS and
Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as
determined by next generation sequencing of small RNA cDNA
libraries. PLoS One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blick C, Ramachandran A, Wigfield S,
McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D,
Catto J, et al: Hypoxia regulates FGFR3 expression via HIF-1α and
miR-100 and contributes to cell survival in non-muscle invasive
bladder cancer. Br J Cancer. 109:50–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiao F, Bai Y, Chen Z, Li Y, Luo L, Huang
J, Yang J, Liao H and Guo L: Downregulation of HOXA1 gene affects
small cell lung cancer cell survival and chemoresistance under the
regulation of miR-100. Eur J Cancer. 50:1541–1554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gebeshuber CA and Martinez J: miR-100
suppresses IGF2 and inhibits breast tumorigenesis by interfering
with proliferation and survival signaling. Oncogene. 32:3306–3310.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng DX, Luo M, Qiu LW, He YL and Wang XF:
Prognostic implications of microRNA-100 and its functional roles in
human epithelial ovarian cancer. Oncol Rep. 27:1238–1244.
2012.PubMed/NCBI
|
|
31
|
Zhu Z, Wang CP, Zhang YF and Nie L:
MicroRNA-100 resensitizes resistant chondrosarcoma cells to
cisplatin through direct targeting of mTOR. Asian Pac J Cancer
Prev. 15:917–923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY,
Lu WG and Xie X: Reduced miR-100 expression in cervical cancer and
precursors and its carcinogenic effect through targeting PLK1
protein. Eur J Cancer. 47:2166–2174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Degenhardt Y and Lampkin T: Targeting
Polo-like kinase in cancer therapy. Clin Cancer Res. 16:384–389.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takaki T, Trenz K, Costanzo V and
Petronczki M: Polo-like kinase 1 reaches beyond mitosis -
cytokinesis, DNA damage response, and development. Curr Opin Cell
Biol. 20:650–660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weichert W, Denkert C, Schmidt M, Gekeler
V, Wolf G, Köbel M, Dietel M and Hauptmann S: Polo-like kinase
isoform expression is a prognostic factor in ovarian carcinoma. Br
J Cancer. 90:815–821. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang X, Fraser M, Abedini MR, Bai T and
Tsang BK: Regulation of apoptosis-inducing factor-mediated,
cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao Q, Huang X, Tang D, Cao Y, Chen G, Lu
Y, Zhuang L, Wang S, Xu G, Zhou J, et al: Influence of chk1 and
plk1 silencing on radiation- or cisplatin-induced cytotoxicity in
human malignant cells. Apoptosis. 11:1789–1800. 2006. View Article : Google Scholar : PubMed/NCBI
|
